The effect of MDA regimes on AMR
We will present the proportions of children with resistant isolates in at baseline (i.e., MDA 1) and at visit 9 for all the trial arms. We will also produce a table with proportions of resistant isolates from all isolates in the same manner as for children with resistant isolates. To estimate the impact of two- or four-dose AZI regimen on the prevalence of phenotypic AZI resistance among If the entire 95% CI for the time point at 1 year after the last MDA in the treatment arms is below a predefined non-inferiority margin of + 10 percent points as compared to the control arm, the sample findings will be considered supportive of the hypothesis of no clinically significant increase in AMR prevalence. The procedure will be same for 49–59-month-old children.